Results 1 to 10 of about 5,546 (214)

Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy [PDF]

Clinical Case Reports, 2019
Key Clinical Message Long‐acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near‐complete tumor excision while restoring pituitary function ...
Terri W. Jerkins, Randy K. Jerkins, Robbi Franklin   +2 more
doaj   +2 more sources

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +4 more sources

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

PLoS ONE, 2019
BackgroundSignaling through mTOR and somatostatin pathway is implicated in thyroid cancer development.MethodWe evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing
Taofeek K Owonikoko, Guojing Zhang, Shenila B Lallani, Zhengjia Chen, Deborah E Martinson, Fadlo R Khuri, Sagar Lonial, Adam Marcus, Shi-Yong Sun   +8 more
doaj   +2 more sources

Real-life data on pasireotide in monotherapy or combined in active Cushing’s disease [PDF]

Frontiers in Endocrinology
IntroductionIn the last few years, the use of medical treatment in Cushing’s disease (CD) has increased thanks to the availability of new molecules. Nevertheless, real-life data on combination treatments are still lacking.MethodsThis is a retrospective ...
Alessandro Mondin, Alessandro Mondin, Filippo Ceccato, Filippo Ceccato, Carla Scaroni, Carla Scaroni, Luca Denaro, Renzo Manara, Renzo Manara, Umberto Maria Robertazzo, Umberto Maria Robertazzo, Mattia Barbot, Mattia Barbot   +12 more
doaj   +2 more sources

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study [PDF]

, 2016
Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism. This analysis reports changes in late-night salivary cortisol (LNSC) during a 12-month, multicentre, Phase ...
Biller, B.M.K., Findling, J.W., Fleseriu, M., Kandra, A., Newell-Price, J., Pedroncelli, A.M., Petersenn, S., Pivonello, R.   +7 more
core   +3 more sources

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature [PDF]

Frontiers in Endocrinology, 2022
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis.
Sandrine Oziel-Taieb, Jemima Maniry-Quellier, Brice Chanez, Flora Poizat, Jacques Ewald, Patricia Niccoli   +5 more
doaj   +2 more sources

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings [PDF]

Frontiers in Endocrinology, 2021
ObjectiveThe aim of the study was to evaluate glucose metabolism, as measured by glycated hemoglobin (HbA1c) levels and the need for antidiabetic medical treatment, in patients with acromegaly resistant to first-generation somatostatin receptors ligands (
Przemysław Witek, Marek Bolanowski, Katarzyna Szamotulska, Agnieszka Wojciechowska-Luźniak, Aleksandra Jawiarczyk-Przybyłowska, Marcin Kałużny   +5 more
doaj   +2 more sources

Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

Journal of Veterinary Internal Medicine, 2017
Background Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
R. Gostelow, C. Scudder, S. Keyte, Y. Forcada, R.C. Fowkes, H.A. Schmid, D.B. Church, S.J.M. Niessen   +7 more
doaj   +4 more sources

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

Drug Design, Development and Therapy, 2012
Georg Golor1, Ke Hu2, Matthieu Ruffin3, Alexandra Buchelt3, Emmanuel Bouillaud3, Yanfeng Wang2, Mario Maldonado31Parexel International GmbH, Berlin, Germany; 2Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Novartis Pharma AG, Basel ...
Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M   +6 more
doaj   +3 more sources

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues [PDF]

Drug Design, Development and Therapy, 2015
Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar ...
Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K   +18 more
doaj   +5 more sources